A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial

Catheterization and Cardiovascular Interventions

Volumn 77, Issue 7, 2011, Pages 1001-1009

  Moliterno, David J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

percutaneous coronary intervention; platelet function; thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG; REPRO; TIROFIBAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BARE METAL STENT; BLEEDING; CONTROLLED STUDY; CORONARY STENT; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; TYROSINE; UNITED STATES;

EID: 79953861913     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22876     Document Type: Article

References (11)

1. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L,; TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-1894. (Pubitemid 32553357)
2. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, Aggarwal A, Kabbani SS, DiBattiste PM,. Increased concentrations of Tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of Tirofiban. Am J Cardiol 2003; 91: 334-336. (Pubitemid 36143875)
3. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, Kabbani SS, DiBattiste PM,. Enhanced early inhibition of platelet aggregation with an increased bolus of Tirofiban. Am J Cardiol 2002; 90: 1421-1423. (Pubitemid 35449499)
4. Herrmann HC, Swierkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW, Klugherz BD, Kolansky DM, Magness K, Valettas N, Wilensky RL,. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2002; 89: 1293-1297. (Pubitemid 34606892)
5. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators,. A clinical trial of abciximab in elective percutaneous coronary intervention after clopidogrel pretreatment. N Engl J Med 2004; 350: 232-238. (Pubitemid 38071801)
6. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH,. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), phase II trial. Ann Intern Med 1991; 115: 256-265.
7. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ,; REPLACE-2 investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-863. (Pubitemid 37430344)
8. Kastrati A, Mehilli J, Neumann F-J, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A,; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538.
9. The ADVANCE Investigators. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. J Am Coll Cardiol 2004; 44: 14-19.
10. van't Hof AW, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JH, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C,; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): A multicentre, double-blind, randomized controlled trial. Lancet 2008: 372: 537-546.
11. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AWJ, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ,. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials. Eur Heart J 2010; 31: 35-49.